🔎 Trials Near Me

Inicio › Cáncer de ovario › Nueva York › New York City

Ensayos clínicos de Cáncer de ovario en New York City, NY

69 estudios para Cáncer de ovario buscan participantes en centros de New York City y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.

Texto oficial del estudio (inglés)

¿Reclutando participantes para un estudio? Destácalo en la parte superior de esta página — $99 por 30 días →

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

ReclutandoFase 1/2
  • Research Site, New York
  • Research Site, New York
Edades de 18 a 130 · Todos los sexos · Actualizado el 5 oct 2026 · NCT05417594

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

ReclutandoFase 2/3
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
  • Memorial Sloan Kettering Cancer Center, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 oct 2026 · NCT07001748

Developing New Educational Materials About Genetic Testing for a Diverse Group of Cancer Patients

Reclutando
  • Memorial Sloan Kettering at Ralph Lauren Center (Limited Protocol Activities), New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 oct 2026 · NCT04751435

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

ReclutandoFase 2
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
  • Mount Sinai Hospital, New York
  • Memorial Sloan Kettering Cancer Center, New York
Todas las edades · Todos los sexos · Actualizado el 5 oct 2026 · NCT05564377

A Study of PHST001 in Advanced Solid Tumors

ReclutandoFase 1
  • Mount Sinai, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 oct 2026 · NCT06840886

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

ReclutandoFase 1
  • NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
  • NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
  • Icahn School of Medicine at Mount Sinai, New York
  • y 2 más
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT06465069

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

ReclutandoFase 1/2
  • Columbia University Medical Center, New York
  • Memorial Sloan Kettering, New York
Edades de 12 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT04585750

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

ReclutandoFase 2
  • Memorial Sloan Kettering Hospital, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT06172478

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

Reclutando
  • Mount Sinai Health System, New York
  • Memorial Sloan Kettering Cancer Center, New York
Edades de 18 en adelante · Mujeres · Actualizado el 29 sept 2026 · NCT05287451

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

ReclutandoFase 1
  • Research Site, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT05877599

Study of AVZO-021 in Patients With Advanced Solid Tumors

ReclutandoFase 1/2
  • Avenzo Therapeutics Recruiting Site, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT05867251

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

ReclutandoEstudio observacional
  • NYU Langone Medical Center, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT04981119

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

ReclutandoFase 1/2
  • Columbia University Medical Center, New York
  • Memorial Sloan Kettering Cancer Center, New York
Edades de 18 en adelante · Mujeres · Actualizado el 25 sept 2026 · NCT03564340

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

ReclutandoFase 1/2
  • Memorial Sloan Kettering Cancer Center, New York
Edades de 18 en adelante · Mujeres · Actualizado el 24 sept 2026 · NCT04590326

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

ReclutandoFase 3
  • Laura and Isaac Perlmutter Cancer Center, New York
  • Icahn School of Medicine at Mount Sinai, New York
  • Memorial Sloan Kettering Cancer Center, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07213804

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

ReclutandoFase 1
  • New York University (NYU) Clinical Cancer Center, New York
  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT07213791

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

ReclutandoFase 2
  • Columbia University Medical Center /ID# 277990, New York
Edades de 18 en adelante · Mujeres · Actualizado el 22 sept 2026 · NCT07059845

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

ReclutandoFase 1/2
  • Columbia University, New York
  • NYU Langone Health, New York
  • Memorial Sloan Kettering Cancer Center, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT06128551

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

ReclutandoFase 1
  • Memorial Sloan Kettering Cancer Center Head Neck Services, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 21 sept 2026 · NCT05983432

BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

ReclutandoFase 1/2
  • Memorial Sloan Kettering Cancer Center, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 18 sept 2026 · NCT04752826

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

ReclutandoFase 3
  • Memorial Sloan Kettering Cancer Center ( Site 0072), New York
Edades de 18 en adelante · Mujeres · Actualizado el 17 sept 2026 · NCT07318558

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

ReclutandoFase 2
  • Laura and Isaac Perlmutter Cancer Center, New York
Edades de 18 a 99 · Mujeres · Actualizado el 15 sept 2026 · NCT07023627

A Study of Isoquercetin in People With Ovarian Cancer

ReclutandoFase 2
  • Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 sept 2026 · NCT07303894

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

ReclutandoFase 1/2
  • Mount Sinai, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT06303505

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

ReclutandoFase 3
  • Columbia University Medical Center, New York
Edades de 18 en adelante · Mujeres · Actualizado el 14 sept 2026 · NCT04575935

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

ReclutandoFase 1
  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 sept 2026 · NCT06293898

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

ReclutandoFase 1
  • New York University (NYU) Clinical Cancer Center, New York
  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 sept 2026 · NCT06400472

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

ReclutandoFase 3
  • Laura and Isaac Perlmutter Cancer Center ( Site 0076), New York
Edades de 18 en adelante · Mujeres · Actualizado el 3 sept 2026 · NCT06824467

Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer

ReclutandoFase 1/2
  • Start Nyli, New York
Edades de 18 en adelante · Mujeres · Actualizado el 1 sept 2026 · NCT07736937

A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

ReclutandoFase 1/2
  • Memorial Sloan Kettering Cancer Center, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 27 ago 2026 · NCT07186842

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

ReclutandoFase 1
  • New York Cancer & Blood Specialists, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 27 ago 2026 · NCT06582017

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

ReclutandoFase 1
  • Icahn School of Medicine at Mount Sinai, New York
Edades de 15 en adelante · Todos los sexos · Actualizado el 25 ago 2026 · NCT06276491

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

ReclutandoFase 1/2
  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
12 Months – 30 Years · Todos los sexos · Actualizado el 25 ago 2026 · NCT04851119

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

ReclutandoFase 1
  • Memorial Sloan Kettering Cancer Center, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 18 ago 2026 · NCT07470853

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

ReclutandoFase 1/2
  • Memorial Sloan Kettering Cancer Center, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 ago 2026 · NCT05985655

Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors

ReclutandoFase 1
  • Xencor Investigative Site, New York
Edades de 18 en adelante · Mujeres · Actualizado el 13 ago 2026 · NCT07593092

Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

ReclutandoFase 1/2
  • Icahn School of Medicine at Mount Sinai Division of Hematology and Medical Oncology, New York
Edades de 18 en adelante · Mujeres · Actualizado el 13 ago 2026 · NCT06040970

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Reclutando
  • Mount Sinai Chelsea, New York
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
  • Mount Sinai West, New York
  • y 4 más
Edades de 35 a 50 · Mujeres · Actualizado el 7 ago 2026 · NCT04251052

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

ReclutandoFase 3
  • Mount Sinai Chelsea, New York
  • Bellevue Hospital Center, New York
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
  • y 3 más
Edades de 18 en adelante · Todos los sexos · Actualizado el 7 ago 2026 · NCT06580314

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

ReclutandoFase 1/2
  • NYU Langone Health, New York
  • Icahn School of Medicine At Mount Sinai Prime, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 ago 2026 · NCT06330064

Clinical Pre-screening Protocol for Ovarian Cancer

ReclutandoEstudio observacional
  • The Blavatnik Family-Chelsea Medical Center at Mount Sinai, New York
Edades de 18 en adelante · Mujeres · Actualizado el 30 jul 2026 · NCT03877796

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

ReclutandoFase 2/3
  • NYU Langone Health, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 jul 2026 · NCT06161025

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

ReclutandoFase 2
  • Columbia University Irving Medical Center, New York
  • Memorial Sloan Kettering Cancer Center, New York
Edades de 8 en adelante · Todos los sexos · Actualizado el 27 jul 2026 · NCT05503797

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

ReclutandoFase 1
  • Investigative Site #103, New York
  • Investigative Site #106, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 jul 2026 · NCT06545942

Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

ReclutandoFase 3
  • Mount Sinai, New York
Edades de 18 en adelante · Mujeres · Actualizado el 14 jul 2026 · NCT05804370

CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer

ReclutandoFase 1/2
  • Mt Sinai Hospital, New York
Edades de 18 a 75 · Mujeres · Actualizado el 13 jul 2026 · NCT07322094

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

ReclutandoFase 2
  • Memorial Sloan Kettering Cancer Center, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 10 jul 2026 · NCT06695845

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

ReclutandoFase 1/2
  • Memorial Sloan Kettering Cancer Center, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 7 jul 2026 · NCT05768139

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

ReclutandoFase 1
  • North Shore Hematology Oncology Associates P.C. DBA New York Cancer and Blood Specialists, New York
  • Columbia University Irving Medical Center, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 jul 2026 · NCT04389632

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

ReclutandoFase 3
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
  • Icahn School of Medicine at Mount Sinai, New York
  • Columbia University, New York
Edades de 18 en adelante · Mujeres · Actualizado el 2 jul 2026 · NCT06819007

A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)

Reclutando
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Edades de 18 en adelante · Mujeres · Actualizado el 1 jul 2026 · NCT05429970

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

ReclutandoFase 1/2
  • New York University Langone Health, New York
  • ICHAN School of Medicine at Mount Sinai, New York
  • Memorial Sloan Kettering Cancer Center, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 29 jun 2026 · NCT05377996

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

ReclutandoFase 1/2
  • NYU Langone Medical Center, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 jun 2026 · NCT06051695

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

ReclutandoFase 2
  • USA04-0, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 may 2026 · NCT06953089

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

ReclutandoFase 1/2
  • Memorial Sloan Kettering Cancer Center, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 may 2026 · NCT03686124

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

ReclutandoFase 3
  • Memorial Sloan-Kettering Cancer Center, New York
Edades de 18 en adelante · Mujeres · Actualizado el 16 abr 2026 · NCT05659381

A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

ReclutandoFase 1
  • Site 0173, New York
Edades de 18 en adelante · Mujeres · Actualizado el 7 abr 2026 · NCT04516447

TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

Reclutando
  • Mount Sinai Hospital, New York
  • Memorial Sloan Kettering Cancer Center, New York
Edades de 25 a 50 · Mujeres · Actualizado el 6 abr 2026 · NCT04294927

Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery

ReclutandoFase 2
  • Memorial Sloan Kettering Cancer Center (All protocol activities), New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 1 abr 2026 · NCT06290193

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

ReclutandoFase 1/2
  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
  • Memorial Sloan Kettering Cancer Center, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 27 mar 2026 · NCT06395519

First in Human Study of TORL-1-23 in Participants With Advanced Cancer

ReclutandoFase 1
  • Memorial Sloan Kettering Cancer Center, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 feb 2026 · NCT05103683

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

ReclutandoFase 1
  • NYU Langone Health, New York
  • Memorial Sloan Kettering Cancer Center, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 feb 2026 · NCT06778863

A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer

ReclutandoFase 1
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 11 feb 2026 · NCT06623396

A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

ReclutandoFase 1
  • NYU Cancer Institute Clinical Cancer Center, New York
  • Memorial Sloan Kettering Cancer Center, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 ene 2026 · NCT06234423

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

ReclutandoEstudio observacional
  • Massive Bio SYNERGY-AI site, New York
Todas las edades · Todos los sexos · Actualizado el 28 oct 2025 · NCT03452774

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

ReclutandoFase 1
  • Exelixis Clinical Site #5, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 sept 2025 · NCT05932862

NYSCF Scientific Discovery Biobank

ReclutandoEstudio observacional
  • New York Stem Cell Foundation Research Institute, New York
30 Days · Todos los sexos · Actualizado el 3 mar 2025 · NCT06203106

Comprehensive Outcomes for After Cancer Health

ReclutandoSe aceptan voluntarios sanos
  • Memorial Sloan Kettering Cancer Center, New York
Edades de 18 en adelante · Todos los sexos · Actualizado el 11 dic 2024 · NCT05349227

Más información sobre Cáncer de ovario en MedlinePlus

Ensayos de Cáncer de ovario en otras ciudades

Otros estudios en New York City

De ClinicalTrials.gov, datos obtenidos el 6 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.